The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Subscribe To Our Newsletter & Stay Updated
